Edition:
United Kingdom

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

1.18USD
12 Dec 2017
Change (% chg)

$-0.01 (-1.26%)
Prev Close
$1.20
Open
$1.19
Day's High
$1.27
Day's Low
$1.15
Volume
47,678
Avg. Vol
47,526
52-wk High
$3.06
52-wk Low
$1.13

Chart for

About

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $23.88
Shares Outstanding(Mil.): 13.92
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131

* CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131

06 Dec 2017

BRIEF-Cellectar Biosciences posts Q3 loss of $0.26 per share

* Cellectar Biosciences reports third quarter 2017 financial and corporate performance

09 Nov 2017

BRIEF-Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma

* Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Cellectar Biosciences announces new preclinical data

* ‍New preclinical data suggest that Cellectar Biosciences' PDC platform provides enhanced outcomes in combination with external radiation​

30 Oct 2017

BRIEF-Cellectar Biosciences gets additional patent for CLR 131, CLR 125 in Japan

* Cellectar Biosciences receives additional Japanese patent for CLR 131 and CLR 125 for the treatment of various solid tumors

17 Oct 2017

BRIEF-Cellectar Biosciences and Pierre Fabre extend collaboration

* Cellectar Biosciences and Pierre Fabre extend collaboration for development of new phospholipid drug conjugates

10 Oct 2017

BRIEF-Cellectar Biosciences reports partial response in a relapsed or refractory multiple myeloma patient treated with CLR 131

* Cellectar Biosciences reports cohort four data and partial response in relapsed or refractory multiple myeloma patient treated with CLR 131

27 Sep 2017

BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics

* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates

21 Sep 2017

BRIEF-Cellectar Biosciences appoints Jarrod Longcor chief business officer

* Cellectar Biosciences appoints Jarrod Longcor chief business officer Source text for Eikon: Further company coverage:

18 Sep 2017

BRIEF-Cellectar Biosciences reports PDC platform advancement

* Cellectar Biosciences announces significant PDC platform advancement; demonstrates potential to improve therapeutic window Source text for Eikon: Further company coverage: (Reporting by Taenaz Shakir)

22 Aug 2017

Earnings vs. Estimates